Search

Allergic rhinitis affects the quality of life of millions of people worldwide. Air pollution not only causes morbidity, but nearly 3 million people per year die from unhealthy indoor air exposure. Furthermore, allergic rhinitis and air pollution interact. This report summarizes the discussion of an International Expert Consensus on the management of allergic rhinitis aggravated by air pollution. The report begins with a review of indoor and outdoor air pollutants followed by epidemiologic evidence showing the impact of air pollution and climate change on the upper airway and allergic rhinitis. Mechanisms, particularly oxidative stress, potentially explaining the interactions between air pollution and allergic rhinitis are discussed. Treatment for the management of allergic rhinitis aggravated by air pollution primarily involves treating allergic rhinitis by guidelines and reducing exposure to pollutants. Fexofenadine a non-sedating oral antihistamine improves AR symptoms aggravated by air pollution. However, more efficacy studies on other pharmacological therapy of coexisting AR and air pollution are currently lacking., Competing Interests: 1. Robert Naclerio: Lyra, Sanofi and Actos (Advisory Board; Speaker), Optinose. 2. Ignacio J Ansotegui.: No conflict of interest to declare. 3. Jean Bousquet: Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi-Aventis, Takeda, Teva, Uriach (Advisory Board, consultant, meeting lectures fees), Kyomed (shares). 4. Giorgio Walter Canonica: BI, ALK, Stallergens (Grant/research support), (Menarini, GSK, Sanofi, Teva, Hal, AZ, Novartis (honoraria or consultation fees). 5. Gennaro D'Amato: No conflict of interest to declare. 6. Nelson Rosario: MSD, GSK, Takeda, Sanofi, Danone, Novartis, Chiesi, AstraZeneca, Aché, FDA Allergenic, Boehringer Ingelheim (speaker); Takeda, MSD, Danone, Boehringer Ingelheim (written material); Danone, MEDA, Sanofi, Boehringer Ingelheim (Advisory). 7. Ruby Pawankar: No conflict of interest to declare. 8. David Peden: No conflict of interest to declare. 9. Karl-Christian Bergmann: No conflict of interest to declare. 10. Leonard Bielory: Allergy Therapeutics, Sanofi, Chattem (consultant), US EPA, CDC (Granta). 11. Luis Caraballo: No conflict of interest to declare. 12. Lorenzo Cecchi: No conflict of interest to declare. 13. S Alfonso M Cepeda: No conflict of interest to declare. 14. Herberto Jose Chong Neto: No conflict of interest to declare. 15. Carmen Galan: No conflict of interest to declare. 16. Sandra N Gonzalez Diaz: No conflict of interest to declare. 17. Samar Idriss: No conflict of interest to declare. 18. Todor A Popov.: No conflict of interest to declare. 19. German Dario Ramon: No conflict of interest to declare. 20. Erminia Ridolo: Faes Pharma (speaker). 21. Menachem Rottem: No conflict of interest to declare. 22. Wisuwat Songnuan: No conflict of interest to declare. 23. Philip Rouadi: GSK, MSD, Astra Zeneca, Bayer, Takeda, Novartis, Meda, Pharmaline, Algorithm, Abbott, Sanofi Pharmaceuticals (Speaker's Desk)., (© 2020 The Authors.)